Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

AM Rx vs OurView Health

AM Rx
Graded #490

Lower grade

vs+17.699999999999996
OurView Health
Graded #162

Higher grade

The verdict

OurView Health takes it — 67.6/100 to 49.9/100.

OurView Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. OurView (OurView Health) is a 100% online multi-vertical telehealth service with an Our View Savings Club membership offering pharmacy-direct pricing on U.S.-compounded medications.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueOurView Health +25
51
76
Dose & formulationAM Rx +1
65
64
Clinical oversightOurView Health +38
41
79
Labs & monitoringOurView Health +4
49
53
FulfillmentOurView Health +12
58
70
Contract termsOurView Health +25
20
45
AM Rx · left barOurView Health · right bar

The numbers

MetricAM RxOurView Health
WeighScore49.9/10067.6/100
GradeCC
Scorecard rank#490#162
Semaglutide$151/mo (quarterly plan, plus a separate fee, compounded)$75/mo (starting dose, compounded)
TirzepatideNot disclosed$135/mo (starting dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
AM Rx

Graded #490 · C

Strengths

  • Insurance coordination for brand-name GLP-1s — as low as $25/mo
  • All four major brand-name GLP-1s available (Ozempic, Wegovy, Zepbound, Mounjaro)
  • HSA and FSA accepted
  • Video visits available with providers averaging 10+ years' experience
  • Compounded semaglutide from $151/mo on the quarterly plan

Where it loses points

  • Active FTC/DOJ lawsuit over deceptive billing and subscription practices
  • Novo Nordisk false-advertising lawsuit (Aug 2025)
  • Parent company Zealthy holds a BBB D- rating with 2,370+ complaints
  • Trustpilot 2.0/5, with 85% one-star reviews citing billing disputes and unreachable support
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
OurView Health

Graded #162 · C

Strengths

  • Low starting prices via the Savings Club — compounded semaglutide from $75, tirzepatide from $135
  • Clear product pricing with no contracts; medication shipped to your door (30-day supply)
  • Full legal suite published (Terms, Privacy, HIPAA Notice, Returns & Refunds)
  • Discloses meds are compounded by a licensed third-party pharmacy; multi-vertical (TRT, HRT, BHRT, peptides)

Where it loses points

  • A comparison table on the site quotes $90 'without membership' against $75 'with membership' while the product cards say 'No membership' and the cart charges $75 without one — the provider contradicts itself on whether a membership exists
  • Both figures are starting-dose rates; the cost of a titrated dose is published as a ladder rather than a single price
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard